article thumbnail

Sana Biotechnology inks $50M deal for precise gene editing system from Beam Therapeutics

GeekWire

Sana Biotechnology has a new $50 million tool in its toolbox. That’s according to a study in Nature Communications led by CRISPR pioneer Feng Zhang at the Broad Institute of MIT and Harvard, which has licensed its technology to Beam. Sana CEO and president Steve Harr. Sana Photo).

article thumbnail

Mars Society gains foothold in AI, robotics and biotechnology to clear a path to space

GeekWire

A biotech prize for turning chemicals into food On the biotechnology front, the Mars Society plans to offer an incentive prize for methods that use microbes to convert simple chemicals, such as methane or methanol, into food. “Ask it anything you want, and you get the answer in multiple personalities,” he said.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Cyrus Biotech spins out company to expand reach of versatile drug development software

GeekWire

LinkedIn Photos) Seattle startup Cyrus Biotechnology is spinning out a business that will expand access to the company’s software technology, with the potential of supporting innovation in drug development, agriculture, synthetic biology and manufacturing.

Software 115
article thumbnail

Seattle-based Icosavax, which is developing COVID-19 vaccines, files for IPO 4 years after launch

GeekWire

Icosavax creates virus-like particles with technology licensed from the University of Washington’s Institute for Protein Design. Pacific Northwest biotechs that have gone public this year include Sana Biotechnology, which raised $587 million in its February IPO and Impel NeuroPharma, which raised $80 million through its IPO in April.

article thumbnail

Cell therapy startup Immusoft lands deal with Takeda worth potentially more than $900M

GeekWire

Under the agreement, Takeda has options to exclusively license programs at the preclinical stage and will take products to the clinic and through commercialization. Ainsworth, a veteran biotech exec, has led the company since 2018 when he replaced Matthew Scholz , who founded the company in 2009 and is now CEO of Oisín Biotechnologies.

article thumbnail

Merck’s multi-billion dollar bet on Seattle Genetics sparks hope for breast cancer treatments

GeekWire

based biotechnology company struck a deal with Merck in which the pharmaceutical powerhouse will provide a $600 million upfront payment and make a $1 billion equity investment to continue development of treatments for breast cancer. Seattle Genetics CEO Clay Siegall. Seattle Genetics Photo). Merck will own about 2.9

article thumbnail

Life sciences startups in Eastern Washington find a welcoming ecosystem away from big cities

GeekWire

Washington State University assistant professor and Appiture Biotechnologies co-founder Georgina Lynch. WSU Photo). The biotech and healthtech community in Eastern Washington has a loyal base of startups that laud their local connections and the support of a tight-knit group of entrepreneurs.